Publication: Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection
Date
Date
Date
Citations
Abela, I. A., Schwarzmüller, M., Ulyte, A., Radtke, T., Haile, S. R., Ammann, P., Raineri, A., Rueegg, S., Epp, S., Berger, C., Böni, J., Manrique, A., Audigé, A., Huber, M., Schreiber, P. W., Scheier, T., Fehr, J., Weber, J., Rusert, P., … Pasin, C. (2024). Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection. MBio, 15, e0272223. https://doi.org/10.1128/mbio.02722-23
Abstract
Abstract
Abstract
Knowledge of the interplay between human coronavirus (HCoV) immunity and severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection is critical to understanding the coexistence of current endemic coronaviruses and to building knowledge potential future zoonotic coronavirus transmissions. This study, which retrospectively analyzed a large cohort of individuals first exposed to SARS-CoV-2 in Switzerland in 2020–2021, revealed several key findings. Pre-existing HCoV immunity, particularly mucosal antibody responses, play
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Keywords
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Metrics
Downloads
Views
Citations
Abela, I. A., Schwarzmüller, M., Ulyte, A., Radtke, T., Haile, S. R., Ammann, P., Raineri, A., Rueegg, S., Epp, S., Berger, C., Böni, J., Manrique, A., Audigé, A., Huber, M., Schreiber, P. W., Scheier, T., Fehr, J., Weber, J., Rusert, P., … Pasin, C. (2024). Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infection. MBio, 15, e0272223. https://doi.org/10.1128/mbio.02722-23